We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Level up your trading with our powerful tools and real-time insights all in one place.
The current SGBCF market cap is 0. The company's latest EPS is CNY and P/E is N/A.
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| CNY (元) | CNY (元) | CNY (元) | CNY (元) | CNY (元) | |
| Total Revenue | 90.93M | 587.59M | 1.68B | 3.21B | 5.39B |
| Operating Income | -838.28M | -897.39M | -856.84M | -622.82M | 703.67M |
| Net Income | -875.47M | -993.54M | -984.05M | -695.26M | 546.02M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| CNY (元) | CNY (元) | CNY (元) | CNY (元) | CNY (元) | |
| Total Assets | 5.9B | 6.44B | 7.17B | 8.92B | 9.9B |
| Total Liabilities | 1.9B | 3.24B | 4.88B | 7.29B | 7.71B |
| Total Equity | 4B | 3.2B | 2.3B | 1.64B | 2.19B |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| CNY (元) | CNY (元) | CNY (元) | CNY (元) | CNY (元) | |
| Operating | -443.13M | -609.58M | 90.39M | 981.62M | 1.05B |
| Investing | -1.13B | -1.51B | -1.68B | -1.36B | -1B |
| Financing | 2.95B | 995.79M | 648.3M | 858.02M | 144.43M |
| Market Cap | 0 |
| Price to Earnings Ratio | N/A |
| Price to Sales Ratio | 0 |
| Price to Cash Ratio | 0 |
| Price to Book Ratio | 0 |
| Dividend Yield | - |
| Shares Outstanding | 163.43M |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 0 |
| 52 Week Change | - |
| 52 Week High | - |
| 52 Week Low | - |
| Spread (Intraday) | 0 (0%) |
| Company Name | Shanghai Henlius Biotech Inc (PK) |
| Address |
room 330, complex building shanghai |
| Website | https://www.henlius.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
